Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H27N5O4 |
Molecular Weight | 389.4495 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CCCN=C(C1CCCO1)O)c2nc3cc(c(cc3c(=N)[nH]2)OC)OC
InChI
InChIKey=WNMJYKCGWZFFKR-UHFFFAOYSA-N
InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
Molecular Formula | C19H27N5O4 |
Molecular Weight | 389.4495 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Alfuzosin is a quinazoline-derivative alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral. UROXATRAL (alfuzosin HCl extended-release tablets) is indicated for the treatment of the
signs and symptoms of benign prostatic hyperplasia. UROXATRAL is not indicated for the treatment of hypertension. Alfuzosin is a non-subtype specific alpha(1)-adrenergic blocking agent that exhibits selectivity for alpha(1)-adrenergic receptors in the lower urinary tract. Inhibition of these adrenoreceptors leads to the relaxation of smooth muscle in the bladder neck and prostate, resulting in the improvement in urine flow and a reduction in symptoms in benign prostate hyperplasia. Alfuzosin also inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9556192
Curator's Comment:: Alfuzosin does not penetrate the blood–brain barrier well
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
8.0 null [pKi] | |||
8.0 null [pKi] | |||
8.5 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | UROXATRAL Approved UseUROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. UROXATRAL is an alpha adrenergic antagonist, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. (1) Important Limitations of Use: UROXATRAL is not indicated for treatment of hypertension. (1.1) UROXATRAL is not indicated for use in the pediatric population. (1.1, 8.4, 12.3) 1.1 Important Limitations of Use UROXATRAL is not indicated for the treatment of hypertension. UROXATRAL is not indicated for use in the pediatric population. Launch Date1.05537602E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.6 ng/mL |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ALFUZOSIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
194 ng × h/mL |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ALFUZOSIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10 h |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ALFUZOSIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14% |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ALFUZOSIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
40 mg 1 times / day single, oral Highest studied dose Dose: 40 mg, 1 times / day Route: oral Route: single Dose: 40 mg, 1 times / day Sources: |
healthy, mean age 27 years n = 45 Health Status: healthy Age Group: mean age 27 years Sex: M Population Size: 45 Sources: |
Other AEs: Dizziness, Headache... Other AEs: Dizziness (8.9%) Sources: Headache (6.7%) Malaise (2%) |
4.4 mg 2 times / day multiple, oral (mean) Recommended Dose: 4.4 mg, 2 times / day Route: oral Route: multiple Dose: 4.4 mg, 2 times / day Sources: |
unhealthy, mean age 62.6 years n = 93 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 62.6 years Sex: M Population Size: 93 Sources: |
Disc. AE: Abdominal pain, Diarrhoea... AEs leading to discontinuation/dose reduction: Abdominal pain (grade 1-2, 1.1%) Sources: Diarrhoea (grade 1-2, 1.1%) Dizziness (grade 1-2, 3.2%) Headache (grade 1-2, 1.1%) Ventricular fibrillation (grade 1-2, 1.1%) |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Disc. AE: Vertigo, Syncope... AEs leading to discontinuation/dose reduction: Vertigo (1.35%) Sources: Syncope (0.55%) Postural hypotension (0.42%) Headache (0.39%) Nausea (0.46%) Abdominal pain (0.35%) Diarrhoea (0.16%) CNS disorder (NOS) (0.14%) Asthenia (0.19%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Malaise | 2% | 40 mg 1 times / day single, oral Highest studied dose Dose: 40 mg, 1 times / day Route: oral Route: single Dose: 40 mg, 1 times / day Sources: |
healthy, mean age 27 years n = 45 Health Status: healthy Age Group: mean age 27 years Sex: M Population Size: 45 Sources: |
Headache | 6.7% | 40 mg 1 times / day single, oral Highest studied dose Dose: 40 mg, 1 times / day Route: oral Route: single Dose: 40 mg, 1 times / day Sources: |
healthy, mean age 27 years n = 45 Health Status: healthy Age Group: mean age 27 years Sex: M Population Size: 45 Sources: |
Dizziness | 8.9% | 40 mg 1 times / day single, oral Highest studied dose Dose: 40 mg, 1 times / day Route: oral Route: single Dose: 40 mg, 1 times / day Sources: |
healthy, mean age 27 years n = 45 Health Status: healthy Age Group: mean age 27 years Sex: M Population Size: 45 Sources: |
Abdominal pain | grade 1-2, 1.1% Disc. AE |
4.4 mg 2 times / day multiple, oral (mean) Recommended Dose: 4.4 mg, 2 times / day Route: oral Route: multiple Dose: 4.4 mg, 2 times / day Sources: |
unhealthy, mean age 62.6 years n = 93 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 62.6 years Sex: M Population Size: 93 Sources: |
Diarrhoea | grade 1-2, 1.1% Disc. AE |
4.4 mg 2 times / day multiple, oral (mean) Recommended Dose: 4.4 mg, 2 times / day Route: oral Route: multiple Dose: 4.4 mg, 2 times / day Sources: |
unhealthy, mean age 62.6 years n = 93 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 62.6 years Sex: M Population Size: 93 Sources: |
Headache | grade 1-2, 1.1% Disc. AE |
4.4 mg 2 times / day multiple, oral (mean) Recommended Dose: 4.4 mg, 2 times / day Route: oral Route: multiple Dose: 4.4 mg, 2 times / day Sources: |
unhealthy, mean age 62.6 years n = 93 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 62.6 years Sex: M Population Size: 93 Sources: |
Ventricular fibrillation | grade 1-2, 1.1% Disc. AE |
4.4 mg 2 times / day multiple, oral (mean) Recommended Dose: 4.4 mg, 2 times / day Route: oral Route: multiple Dose: 4.4 mg, 2 times / day Sources: |
unhealthy, mean age 62.6 years n = 93 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 62.6 years Sex: M Population Size: 93 Sources: |
Dizziness | grade 1-2, 3.2% Disc. AE |
4.4 mg 2 times / day multiple, oral (mean) Recommended Dose: 4.4 mg, 2 times / day Route: oral Route: multiple Dose: 4.4 mg, 2 times / day Sources: |
unhealthy, mean age 62.6 years n = 93 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 62.6 years Sex: M Population Size: 93 Sources: |
CNS disorder (NOS) | 0.14% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Diarrhoea | 0.16% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Asthenia | 0.19% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Abdominal pain | 0.35% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Headache | 0.39% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Postural hypotension | 0.42% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Nausea | 0.46% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Syncope | 0.55% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Vertigo | 1.35% Disc. AE |
2.5 mg 3 times / day multiple, oral Recommended Dose: 2.5 mg, 3 times / day Route: oral Route: multiple Dose: 2.5 mg, 3 times / day Sources: |
unhealthy, mean age 66.9 years n = 13389 Health Status: unhealthy Condition: benign prostatic hypertrophy Age Group: mean age 66.9 years Sex: M Population Size: 13389 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21287_uroxatral_lbl.pdf#page=5 Page: 5.0 |
no | |||
no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21287_uroxatral_lbl.pdf#page=5 Page: 5.0 |
no | |||
no | ||||
no | ||||
no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21287_uroxatral_lbl.pdf#page=5 Page: 5.0 |
no | |||
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | yes (co-administration study) Comment: administration with ketoconazole increased alfuzosin Cmax and AUClast by, 2.3-fold and 3.2 fold, respectively; administration with diltiazem increased Cmax and AUC0-24 of alfuzosin 1.5-fold and 1.3-fold, respectively; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-287_Uroxatral_BioPharmr_P1.pdf#page=34 Page: 34.0 |
|||
minor |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-287_Uroxatral_Pharmr_P1.pdf#page=27 Page: 27,28 |
PubMed
Title | Date | PubMed |
---|---|---|
Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia. | 2001 |
|
Initial choices and final outcomes in lower urinary tract symptoms. | 2001 |
|
Long-term aspects of medical treatment of BPH. | 2001 |
|
Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. | 2001 |
|
alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. | 2001 Jan |
|
[Dalphaz-retard treatment of urination disorders in men and women]. | 2001 Jul-Aug |
|
[Long-term therapy of benign prostatic hyperplasia. Our experience]. | 2001 Mar |
|
Do alpha-blockers prevent the occurrence of acute urinary retention? | 2001 Mar |
|
Does acute urinary retention respond to alpha-blockers alone? | 2001 Mar |
|
Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. | 2001 Mar |
|
Worldwide experience with alfuzosin and tamsulosin. | 2001 Oct |
|
Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. | 2002 |
|
Alfuzosin: a clinically uroselective alpha1-blocker. | 2002 Apr |
|
Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. | 2002 Apr |
|
Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. | 2002 Dec 12 |
|
Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. | 2002 Jan |
|
[Comparative evaluation of the effectiveness and safety of combined drug therapy of patients with benign prostatic hyperplasia with finasteride and alfuzozine]. | 2002 Jan-Feb |
|
Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects. | 2002 Jul |
|
Alfuzosin in the treatment of high leak-point pressure in children with neurogenic bladder. | 2002 Nov |
|
[Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers. Basic principles and clinical results]. | 2002 Sep |
|
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. | 2003 Aug |
|
Use of alpha-blockers and the risk of hip/femur fractures. | 2003 Dec |
|
Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. | 2003 Jul |
|
Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum. | 2003 Jun |
|
Selective, sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of alfuzosin in human plasma. | 2003 May 25 |
|
First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. | 2003 Nov |
|
Alfuzosin for the management of benign prostate hyperplasia. | 2003 Nov |
|
Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. | 2003 Sep |
|
[Pharmacologic treatment of benign prostatic hyperplasia]. | 2003 Sep 14 |
|
A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes. | 2004 |
|
Priapism as a possible acute side effect of radical radiotherapy for prostate cancer. | 2004 Apr |
|
Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. | 2004 Apr |
|
Ejaculatory dysfunction and alpha-adrenoceptor antagonists. | 2004 Aug |
|
Real life practice in the management of benign prostatic hyperplasia. | 2004 Jan |
|
Alfuzosin (uroxatral)--another alpha1-blocker for benign prostatic hyperplasia. | 2004 Jan 5 |
|
[Can selective alpha-blockers help the spontaneous passage of the stones located in the uretero-bladder junction?]. | 2004 Jan-Mar |
|
[A suggested treatment algorithm in nocturnal enuresis with emphasis on partial responders]. | 2004 Jul |
|
Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. | 2004 Jun |
|
Patients with bladder outlet obstruction who refuse treatment show no clinical and urodynamic change after long-term follow-up. | 2004 Mar |
|
Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. | 2004 Mar |
|
New drugs of 2003. | 2004 Mar-Apr |
|
Prostate size influences the outcome after presenting with acute urinary retention. | 2004 Sep |
|
Alfuzosin-induced acute hepatitis in a patient with chronic liver disease. | 2004 Sep |
|
Clinical assessment of drug-induced QT prolongation in association with heart rate changes. | 2005 Apr |
|
Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin. | 2005 Aug |
|
Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. | 2005 Aug |
|
A pharmacoepidemiological approach to investigating inappropriate physician prescribing in a managed care setting in Israel. | 2005 Feb |
|
[The role of alpha1-adrenoblocker alfuzosine in diagnostic-therapeutic algorithm of hyperactive urinary bladder management in women and selection of patients for treatment with M-cholinergic antagonists]. | 2005 Jan-Feb |
|
Re: Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. | 2005 Jul |
|
Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. | 2005 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/alfuzosin.html
Usual Adult Dose for Benign Prostatic Hyperplasia
Extended-release tablet: 10 mg orally once a day immediately after the same meal each day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19428174
In organ baths, isolated prostatic strips and isolated bladder strips were incubated with vehicle, tadalafil (10⁻⁶ M and 10⁻⁵ M), alfuzosin (3×10⁻⁸ M or 10⁻⁶ M and 10⁻⁵ M) or a combination. Concentration-response curves (CRCs) to norepinephrine were generated on prostatic strips and detrusor strips precontracted with carbachol. Strips were also submitted to electrical field stimulation (EFS). When alfuzosin and tadalafil were combined, the maximal relaxation to norepinephrine on carbachol-precontracted detrusor strips was significantly increased compared with tadalafil alone, and EFS-induced detrusor contractions were better inhibited compared with each compound alone. Tadalafil significantly inhibited norepinephrine-induced prostatic strip contractions by reducing the maximal effect, whereas alfuzosin shifted the CRC of norepinephrine to the right. Combining both tadalafil and alfuzosin resulted in a greater relaxant effect.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:51:53 UTC 2021
by
admin
on
Fri Jun 25 21:51:53 UTC 2021
|
Record UNII |
90347YTW5F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
G04CA51
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
||
|
WHO-VATC |
QG04CA51
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
||
|
WHO-VATC |
QG04CA01
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
||
|
LIVERTOX |
24
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
||
|
NDF-RT |
N0000175553
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
||
|
NDF-RT |
N0000000099
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
||
|
NCI_THESAURUS |
C29713
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
||
|
WHO-ATC |
G04CA01
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00346
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
PRIMARY | |||
|
17300
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
PRIMARY | RxNorm | ||
|
5357
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
PRIMARY | |||
|
90347YTW5F
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
PRIMARY | |||
|
SUB05319MIG
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
PRIMARY | |||
|
M1501
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
PRIMARY | Merck Index | ||
|
ALFUZOSIN
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
PRIMARY | |||
|
2092
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
PRIMARY | |||
|
7109
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
PRIMARY | |||
|
81403-80-7
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
PRIMARY | |||
|
81403-80-7
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
PRIMARY | |||
|
7290
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
PRIMARY | |||
|
115
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
PRIMARY | |||
|
C61627
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
PRIMARY | |||
|
CHEMBL709
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
PRIMARY | |||
|
C047638
Created by
admin on Fri Jun 25 21:51:53 UTC 2021 , Edited by admin on Fri Jun 25 21:51:53 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> INHIBITOR | |||
|
EXCRETED UNCHANGED |
AMOUNT EXCRETED
URINE
|
||
|
TARGET -> AGONIST | |||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
in vitro
|
||
|
METABOLITE INACTIVE -> PARENT |
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
FECAL
|
||
|
METABOLITE INACTIVE -> PARENT |
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
FECAL
|
||
|
METABOLITE INACTIVE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT |
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
FECAL
|
||
|
METABOLITE INACTIVE -> PARENT |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||